Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma
Open Access
- 4 April 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Genitourinary Cancer
- Vol. 19 (5), e306-e312
- https://doi.org/10.1016/j.clgc.2021.03.019
Abstract
No abstract availableFunding Information
- Pfizer Foundation
This publication has 20 references indexed in Scilit:
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaThe New England Journal of Medicine, 2019
- Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyJournal for ImmunoTherapy of Cancer, 2018
- The pathophysiology of cancer-related fatigue: current controversiesSupportive Care in Cancer, 2018
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialThe Lancet Oncology, 2018
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trialThe Lancet Oncology, 2018
- Resilience and positive affect contribute to lower cancer‐related fatigue among Chinese patients with gastric cancerJournal of Clinical Nursing, 2017
- Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapyDrug Design, Development and Therapy, 2017
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trialThe Lancet Oncology, 2013
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Cancer-related fatigue: prevalence, assessment and treatment strategiesExpert Review of Pharmacoeconomics & Outcomes Research, 2011